After many years of development, therapeutic antibody products have demonstrated significant success in the clinic and commercial markets. In addition to the APC technology that uses recombinant antibody technology, Celldex is also developing therapeutic human monoclonal antibody products. Our lead programs are for oncology targets. Celldex has access through a research and commercialization agreement with Medarex to the UltiMAb® Technology for generating fully human monoclonal antibodies. Under this agreement, Celldex can exercise up to ten separate licenses to develop and commercialize therapeutic antibody products. One program under this agreement is currently in preclinical development.
For citations related to human antibody technologies and CD89 targeting click here